Market closedNon-fractional

Zentalis Pharmaceuticals/ZNTL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Ticker

ZNTL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

New York, United States

Employees

124

ZNTL Metrics

BasicAdvanced
$257M
Market cap
-
P/E ratio
-$3.20
EPS
1.83
Beta
-
Dividend rate
$257M
1.83
9.194
8.923
9.289
9.886
-24.93%
-51.87%
6.097
0.56
0.57
-1.171
-25.10%
-8.03%

What the Analysts think about ZNTL

Analyst Ratings

Majority rating from 11 analysts.
Buy

ZNTL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
24.69% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
∞%
Net income
$10M
-116.42%
Profit margin
24.69%
∞%

ZNTL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 118.26%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.85
-$0.79
-$0.93
$0.14
-
Expected
-$1.04
-$0.91
-$0.92
-$0.77
-$0.86
Surprise
78.31%
-13.35%
1.54%
-118.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Zentalis Pharmaceuticals stock?

Zentalis Pharmaceuticals (ZNTL) has a market cap of $257M as of July 06, 2024.

What is the P/E ratio for Zentalis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Zentalis Pharmaceuticals (ZNTL) stock is 0 as of July 06, 2024.

Does Zentalis Pharmaceuticals stock pay dividends?

No, Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Zentalis Pharmaceuticals dividend payment date?

Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders.

What is the beta indicator for Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (ZNTL) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Zentalis Pharmaceuticals stock

Buy or sell Zentalis Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing